Instructions for presentations

Technical requirements


Please note: All poster presenters must prepare one poster as well as one PowerPoint presentation.

Submitted abstracts will be presented in 6 parallel moderated sessions. Each session will be organized in a separate part of the exhibition hall, with each session area containing one large TV-screen for the moderated data presentation, as well as posters for subsequent individual presentations.

In the first part of the poster session, all authors will be given 3 min to present key figures/tables from their poster in a PowerPoint presentation. The presentation will be followed by a 4 min moderated discussion. The moderators will be responsible for keeping time in all sessions.

For the second part of the poster sessions, the presenting author should be present at their poster for individual feedback, questions and discussions, and an opportunity to visit posters in parallel sessions.

As in previous years, invited lecturers will act as referees in all poster sessions, selecting the three best presentations and a poster price of NOK 5000,- for the winner in each session. Posters will be evaluated based on: 1. Novelty of conclusions, 2. Quality of data, and 3. Clarity of presentation.

- POSTER: Recommended Poster Size: 90x120cm (Portrait)


Compulsory format for PowerPoint presentations in the moderated poster sessions:

• Every slide (all 6 in every presentation) must be clearly labeled with the abstract/poster number in the top left corner. This number will be available and provided upon confirmed acceptance of the abstract.
• The presentation is limited to 6 slides with no animations, videos or sequential build-up of individual slides.
• Slide 1 should contain the abstract title, list of authors and affiliations only.
• Slide 2-5 should contain a brief introduction and clearly stated hypothesis if deemed necessary, as well as results from the abstract and poster, preferably as figures and/or tables.
• Slide 6 should contain summary and/or conclusion(s) in bullet points.

Technical requirements:

• Microsoft PowerPoint on a Windows based PC will be used for all presentations.
• Slides must be fitted screen with aspect ratio Standard (4:3) or Widescreen (16:9). Resolution: e.g. 1024×768, 1280×960 or 1280x720, 1920x1080.
• Use the “Insert” feature of PowerPoint to add images to your presentations. Do not copy/paste images into the slide or click and drag.
• Ensure no videos or animations are included in the presentation. No animated bullet points.
• Please note that Internet access will not be available.
• No sound system will be connected to the computer.
• The following file types are the only acceptable:

  • Microsoft Office PowerPoint Presentation (.pptx)
  • Microsoft Office PowerPoint 97-2003 Presentation (.ppt)

- INSTRUCTIONS FOR SUBMITTING PRESENTATIONS: Please enter Poster number when submitting your presentation.

- LIST OF ACCEPTED PRESENTATIONS, 17th Annual CHFR Symposium on Heart Research
Poster number, Name and Abstract title

Session I Biomarkers and Cardiac Disease
I-1 Pope MKP “Risk profile, Antithrombotic Treatment and Clinical Outcomes for Patients in Nordic Countries with Atrial Fibrillation Results from the …”
I-2 Kalstad AA “Circulating sirtuin 1 (SIRT1) levels are inversely associated with atrial fibrillation in elderly patients with ischemic heart disease”
I-3 Johannessen TR “Prehospital assessment of the One-hoUr rule-in/rule-out algorithm using a high-sensitivity cardiac Troponin T assay in a …”
I-4 Tveit SH “Cardiac troponin I measured with a single molecule counting assay for ruling out coronary artery disease in patients with stable chest pain”
I-5 Skranes JB “The high-sensitivity cardiac troponin I and T response following strenuous activity is attenuated by smokeless tobacco: The North Sea …”
I-6 Erevik CB “There are no differences in global myocardial function between high- and normal troponin responders following strenuous …”
I-7 Myhre PL “Cardiac Troponin T and N-terminal pro-B-type natriuretic peptide for detection of Myocardial Ischemia among Patients with Suspected …”
I-8 Shetelig C “Circulating levels of ST2 are associated with myocardial injury, left ventricular function and future adverse clinical events in patients with...”
I-9 Blom KB “Cardiovascular rEmodelling in living kidNey donorS with reduced glomerular filtration rate: Rationale and design of the CENS study”
I-10 Opstad TB “Shorter leukocyte telomere lengths in healthy relatives of CHD patients”
I-11 Kvisvik B “High-sensitivity troponin T predicts mortality independently of ventricular dysfunction and pulmonary hypertension in stable chronic…”
I-12 Sithiravel C “Growth differentiation factor-15 predicts adverse outcome in stable chronic obstructive pulmonary disease patients independently of…”

Session II Cellular Signaling: Myocardial Hypertrophy and Ischemia
II-1 Nordén ES “Sacubitril/Valsartan: Influence of time and infarction size on cardio-protective effects”
II-2 Altara R “The cardio protective effects of proANP 31-67 in cardiac hypertrophy”
II-3 Rypdal KB “The secreted cardiac fibroblast glycoprotein ADAMTSL2 is up-regulated in heart failure and directs anti-fibrotic signaling”
II-4 Machiedo SS / Birgisdottir ÅB “Transcriptional control of adrenomedullin during hypoxia in cardiac myoblasts and endothelial cells”
II-5 Frisk M “T-tubule disruption is a prominent feature of HFrEF but not HFpEF”
II-6 Zaidi H “Effects of long-term exercise training on markers of remodeling in patients with T2DM and CAD”
II-7 Lockwood F “Syndecan-4 regulates integrin expression in cardiac remodeling”
II-8 Romaine A “Syndecan-4 drives pathological cardiac remodelling through integrin regulation”
II-9 Veras I “Texture analysis applied on T1 mapping images for assessment of myocardial fibrosis: a magnetic resonance study”

Session III Cardiac Function During Heart Failure and Exercise Training
III-1 Pristaj N “Sex-specific Covariates of Subclinical Myocardial Dysfunction in Subjects with Increased Body Mass Index”
III-2 Langlo KAR “The associations of renal function with heart failure phenotypes according to the new ESC classification”
III-3 Rolid K “Comparison of associations between self-reported physical function and exercise capacity early and 1 year after heart transplantation”
III-4 Rolid K “Effect of high intensity interval training on health related quality of life in de novo heart transplant recipients – a substudy of the HITTS study”
III-5 Kleiven Ø “Endurance exercise volume is not associated with the progression of coronary artery calcification; a longitudinal coronary computed…”
III-6 Bendiksen BA “Myocardial Deformation Based on a 4D Continuous Approximation Myocardial Velocity Fields Measured by Tissue Phase Mapping …”
III-7 Espe E “Three-dimensional analysis of myocardial function in post-MI rat hearts: a magnetic resonance study”
III-8 Sletten OJ “Left ventricular global work is superior to global strain for assessing ventricular function during elevated afterload”
III-9 Einarsen E “Higher arterial stiffness is associated with lower first-phase ejection fraction in aortic stenosis”
III-10 Kirkels FP “Echocardiographic deformation imaging in arrhythmogenic cardiomyopathy: combining strain pattern recognition with mechanical…”
III-11 Skjølsvik ET “Exercise is associated with impaired left ventricular function in patients with Lamin A/C mutations”

Session IV Cellular Signaling: Myocardial Function and Arrhythmias
IV-1 Skogestad J “Phosphodiesterase 2 inhibition activates the Na+/K+-ATPase and prevents ventricular tachycardia”
IV-2 Sadredini M “Inhibition of CaMKII increases Ca 2+ alternans in cardiomyocytes from mice with a gainoffunction ryanodine receptor mutation”
IV-3 Hou Y “Correlating spontaneous calcium release events with molecular RyR2 distribution in live cardiomyocytes”
IV-4 Shen X “Hyper-Phosphorylation Promotes Ryanodine Receptor Dispersion and Disrupted Ca 2+ Homeostasis in Failing Cardiomyocytes”
IV-5 Kolstad T “SERCA Loss Promotes Remodeling of the Sarcoplasmic Reticulum During Heart Failure”
IV-6 Li J “Stretch synchronizes sarcomere shortening in cardiomyocytes: implications for the Frank-Starling Mechanism”
IV-7 Andresen H “A search for a new allosteric binding site on the natriuretic peptide receptor A”
IV-8 Calamera G “New FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons”
IV-9 Ndongson B “Early changes in cardiac performance caused by calcineurin inhibitors – a marker of long-term organ toxicity?”

Session V Diagnostic and Therapeutical Strategies for Cardiac Disease
V-1 Ødegaard KM “Incidence, prevalence and survival in heart failure: a nationwide registry study from 2011-2016”
V-2 Traaen GM “Prevalence and clinical predictors of sleep apnea in patients with paroxysmal atrial fibrillation”
V-3 Kvaslerud AB “Long term outcomes in asymptomatic patients with severe aortic stenosis”
V-4 Chivulescu M “High penetrance and similar disease progression in probands and family members with arrhythmogenic cardiomyopathy”
V-5 Khan FH “Left atrial strain improves estimation of left ventricular filling pressure”
V-6 Larsen CK “Septal negative work correlates inversely with septal scar in patients referred for cardiac resynchronization therapy”
V-7 Harbo MB “Revealing the Detailed Myocardial Response to Infarction in Humans”
V-8 Smith L “Phantom experiments to validate preclinical cardiac MR Elastography”
V-9 Andreassen K “MRI-based evaluation of regional hypertrophy in a mouse model of hypertrophic cardiomyopathy”
V-10 Henriksen IM “Semi-Automatic Segmentation of CINE Magnetic Resonance Images"

Session VI Inflammatory Mediators and Metabolism
VI-1 Prestgaard E “Change in Body Mass Index and Long-term Risk of Stroke in Healthy Men”
VI-2 Awoyemi A “The effects of Diet intervention and Omega-3 supplementation on gut microbiota. Association with cardiovascular outcome”
VI-3 Bratseth V “Thrombogenicity in children with type 1 diabetes – A case control study”
VI-4 Mayerhoferc CK “Low Fiber Intake is Associated with Gut Microbiota Alterations in Chronic Heart Failure”
VI-5 Schots PC “Impact of anti-obesogenic interventions of the gut microbiome”
VI-6 Gustafsson B “Epicardial adipose tissue and diastolic dysfunction in middle-aged individuals”
VI-7 Sæther J “Circulating lipoprotein subfractions as new non-invasive biomarkers of coronary atherosclerosis”
VI-8 Brautaset KV “Prevalence of Iron Deficiency in Heart Transplant Recipients”
VI-9 Helseth R “Neutrophil extracellular trap components associate with infarct size, ventricular function and clinical outcome in STEMI”
VI-10 Langseth MS “Markers of neutrophil extracellular traps in post-ischemic acute heart failure: Associations with myocardial function and interleukin 8...”
VI-11 Kluge KE “Complement activation by TCC and neutrophil extracellular traps in stable coronary artery disease”
VI-12 Drapkina OM / Kaburova AN. “Comparison of the gut microbiota composition between the group of heart failure with preserved ejection fraction …”

Webmaster Vidar, IEMF